MedTrace Logo

Addition of microRNA Blood Test to Lung Cancer Screening Low Dose CT

NCT03452514 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 479

Last updated 2021-02-25

No results posted yet for this study

Summary

To demonstrate that the specificity of the Hummingbird microRNA profile for the diagnosis of lung cancer in a cohort of patients who meet current eligibility criteria for lung cancer screening in the U.S. is superior to the specificity of LDCT.

Conditions

Sponsors & Collaborators

  • Hummingbird Diagnostics

    lead INDUSTRY

Principal Investigators

  • Amita Sharma, MD · Massachusetts General Hospital

Eligibility

Min Age
55 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-01
Primary Completion
2020-09-14
Completion
2020-09-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03452514 on ClinicalTrials.gov